Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Jun;63(6):945–952. doi: 10.1038/bjc.1991.207

A critical analysis of prognostic factors for survival in intermediate and high grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group Therapy Working Party.

R L Hayward 1, R C Leonard 1, R J Prescott 1
PMCID: PMC1972546  PMID: 2069849

Abstract

Between 1979 and 1987 the Scotland and Newcastle Lymphoma Group registered 972 adults with Working Formulation high or intermediate grade non-Hodgkin's lymphoma. Clinical, pathological and investigational data were recorded prospectively on a computer database allowing analysis for prognostic factors. We have derived prognostically important characteristics and have tested prospectively the validity of the prognostic index on a geographically distinct sub-set of patients from the Edinburgh/Borders clinics. Multivariate analysis showed the following factors to be important in declining order of power; advancing age, worsening performance status, CNS/liver involvement, abnormal white cell count, 'B' symptoms and advancing clinical stage. Patient individual scores allowed them to be aggregated into one of three distinct prognostic groupings separated by arbitrary cut-points into a Best Group (39%) where the median survival exceeds 5 years (53% alive at 5 years), an Intermediate Group (30%) with median survival of 21 months (21% alive at 5 years), and a Worst Group (31%) whose median survival is 7 months (8% alive at 5 years). Similar prognostic group separations occurred when analysis was confined to: patients younger than 70 years; patients treated with initial chemotherapy; patients treated with initial radiotherapy; patients within any of the major pathological sub-groups.

Full text

PDF
945

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Katib A., Koziner B., Kurland E., Little C., Labriola D., Thaler H., Straus D., Lee B., Clarkson B. Treatment of diffuse poorly differentiated lymphocytic lymphoma. An analysis of prognostic variables. Cancer. 1984 Jun 1;53(11):2404–2412. doi: 10.1002/1097-0142(19840601)53:11<2404::aid-cncr2820531107>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  2. Armitage J. O., Cheson B. D. Interpretation of clinical trials in diffuse large-cell lymphoma. J Clin Oncol. 1988 Aug;6(8):1335–1347. doi: 10.1200/JCO.1988.6.8.1335. [DOI] [PubMed] [Google Scholar]
  3. Armitage J. O., Dick F. R., Corder M. P., Garneau S. C., Platz C. E., Slymen D. J. Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer. 1982 Nov 1;50(9):1695–1702. doi: 10.1002/1097-0142(19821101)50:9<1695::aid-cncr2820500907>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  4. Bloomfield C. D., Goldman A., Dick F., Brunning R. D., Kennedy B. J. Multivariate analysis of prognostic factors in the non-Hodgkin's malignant lymphomas. Cancer. 1974 Mar;33(3):870–879. doi: 10.1002/1097-0142(197403)33:3<870::aid-cncr2820330337>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  5. Bonadonna G., Lattuada A., Banfi A. Recent trends in the treatment of non-Hodgkin's lymphomas. Eur J Cancer. 1976 Sep;12(9):661–673. doi: 10.1016/0014-2964(76)90013-x. [DOI] [PubMed] [Google Scholar]
  6. Boyd D. B., Coleman M., Papish S. W., Topilow A., Kopel S. K., Bernhardt B., Files J. C., Schwartz S., Gaynor M., McDermott D. COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma. J Clin Oncol. 1988 Mar;6(3):425–433. doi: 10.1200/JCO.1988.6.3.425. [DOI] [PubMed] [Google Scholar]
  7. Cabanillas F., Burke J. S., Smith T. L., Moon T. E., Butler J. J., Rodriguez V. Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma. Arch Intern Med. 1978 Mar;138(3):413–418. [PubMed] [Google Scholar]
  8. Danieu L., Wong G., Koziner B., Clarkson B. Predictive model for prognosis in advanced diffuse histiocytic lymphoma. Cancer Res. 1986 Oct;46(10):5372–5379. [PubMed] [Google Scholar]
  9. DeVita V. T., Jr, Canellos G. P., Chabner B., Schein P., Hubbard S. P., Young R. C. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet. 1975 Feb 1;1(7901):248–250. doi: 10.1016/s0140-6736(75)91142-3. [DOI] [PubMed] [Google Scholar]
  10. Dixon D. O., Neilan B., Jones S. E., Lipschitz D. A., Miller T. P., Grozea P. N., Wilson H. E. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol. 1986 Mar;4(3):295–305. doi: 10.1200/JCO.1986.4.3.295. [DOI] [PubMed] [Google Scholar]
  11. Fisher R. I., DeVita V. T., Jr, Hubbard S. M., Longo D. L., Wesley R., Chabner B. A., Young R. C. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med. 1983 Mar;98(3):304–309. doi: 10.7326/0003-4819-98-3-304. [DOI] [PubMed] [Google Scholar]
  12. Fisher R. I., DeVita V. T., Jr, Johnson B. L., Simon R., Young R. C. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med. 1977 Aug;63(2):177–182. doi: 10.1016/0002-9343(77)90230-3. [DOI] [PubMed] [Google Scholar]
  13. Honegger H. P., Cavalli F. Current status and perspectives in the treatment of non-Hodgkin's lymphomas. Eur J Cancer Clin Oncol. 1984 Mar;20(3):305–314. doi: 10.1016/0277-5379(84)90074-9. [DOI] [PubMed] [Google Scholar]
  14. Horning S. J., Doggett R. S., Warnke R. A., Dorfman R. F., Cox R. S., Levy R. Clinical relevance of immunologic phenotype in diffuse large cell lymphoma. Blood. 1984 May;63(5):1209–1215. [PubMed] [Google Scholar]
  15. Kaminski M. S., Coleman C. N., Colby T. V., Cox R. S., Rosenberg S. A. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med. 1986 Jun;104(6):747–756. doi: 10.7326/0003-4819-104-6-747. [DOI] [PubMed] [Google Scholar]
  16. Laurence J., Coleman M., Allen S. L., Silver R. T., Pasmantier M. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Ann Intern Med. 1982 Aug;97(2):190–195. doi: 10.7326/0003-4819-97-2-190. [DOI] [PubMed] [Google Scholar]
  17. Leonard R. C., Cuzick J., MacLennan I. C., Vanhegan R. I., Mackie P. H., McCormick C. V. Prognostic factors in non-Hodgkin's lymphoma: the importance of symptomatic stage as an adjunct to the Kiel histopathological classification. Br J Cancer. 1983 Jan;47(1):91–102. doi: 10.1038/bjc.1983.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Monfardini S., Rilke F., Valagussa P., Bajetta E., Canetta R., Buzzoni R., Giardini R., Viviani S. A clinicopathologic study in advanced non-Hodgkin's lymphomas treated with sequential non-cross-resistant regimens: comparison of the working formulation with the Rappaport and Kiel classifications. Eur J Cancer Clin Oncol. 1984 May;20(5):609–617. doi: 10.1016/0277-5379(84)90005-1. [DOI] [PubMed] [Google Scholar]
  19. Schein P. S., Chabner B. A., Canellos G. P., Young R. C., Berard C., DeVita V. T. Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin's lymphoma. Blood. 1974 Feb;43(2):181–189. [PubMed] [Google Scholar]
  20. Shipp M. A., Harrington D. P., Klatt M. M., Jochelson M. S., Pinkus G. S., Marshall J. L., Rosenthal D. S., Skarin A. T., Canellos G. P. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med. 1986 Jun;104(6):757–765. doi: 10.7326/0003-4819-104-6-757. [DOI] [PubMed] [Google Scholar]
  21. Stein R. S., Cousar J., Flexner J. M., Graber S. E., McKee L. C., Krantz S., Collins R. C. Malignant lymphomas of follicular center cell origin in man. III. Prognostic features. Cancer. 1979 Dec;44(6):2236–2243. doi: 10.1002/1097-0142(197912)44:6<2236::aid-cncr2820440635>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  22. Steward W. P., Todd I. D., Harris M., Jones J. M., Blackledge G., Wagstaff J., Anderson H., Wilkinson P. M., Crowther D. A multivariate analysis of factors affecting survival in patients with high-grade histology non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol. 1984 Jul;20(7):881–889. doi: 10.1016/0277-5379(84)90159-7. [DOI] [PubMed] [Google Scholar]
  23. Trump D. L., Mann R. B. Diffuse large cell and undifferentiated lymphomas with prominent mediastinal involvement. Cancer. 1982 Jul 15;50(2):277–282. doi: 10.1002/1097-0142(19820715)50:2<277::aid-cncr2820500218>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES